Zacks Research Upgrades Alvotech (NASDAQ:ALVO) to "Hold"

Alvotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research upgraded Alvotech from “strong sell” to “hold.” Despite the upgrade, analyst sentiment overall remains “Moderate Buy,” with an average price target of $8.40.
  • Alvotech shares were down 5.7% and opened at $4.29 on Wednesday, within a 52-week range of $2.94 to $6.53.
  • The company’s quarterly loss of $0.03 per share matched estimates, while revenue of $111.6 million fell short of the $123.45 million consensus.
  • Interested in Alvotech? Here are five stocks we like better.

Alvotech (NASDAQ:ALVO - Get Free Report) was upgraded by equities researchers at Zacks Research from a "strong sell" rating to a "hold" rating in a note issued to investors on Wednesday, Zacks reports.

Several other research firms have also issued reports on ALVO. Weiss Ratings raised shares of Alvotech from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, November 4th. Evercore started coverage on Alvotech in a research note on Friday, August 14th. They set an "outperform" rating for the company. Bank of America began coverage on Alvotech in a report on Monday, August 24th. They set a "buy" rating and a $7.00 price objective on the stock. Wall Street Zen raised Alvotech from a "sell" rating to a "hold" rating in a research note on Sunday, November 15th. Finally, UBS Group set a $8.00 target price on Alvotech in a report on Wednesday, September 16th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Alvotech presently has a consensus rating of "Moderate Buy" and an average price target of $8.40.

Read Our Latest Report on ALVO

Alvotech Stock Down 5.7%

ALVO opened at $4.29 on Wednesday. Alvotech has a fifty-two week low of $2.94 and a fifty-two week high of $6.53. The business has a 50-day moving average of $5.16 and a 200-day moving average of $4.18.

Alvotech (NASDAQ:ALVO - Get Free Report) last announced its quarterly earnings results on Wednesday, November 11th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $111.60 million during the quarter, compared to the consensus estimate of $123.45 million. As a group, sell-side analysts anticipate that Alvotech will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALVO. Citadel Advisors LLC bought a new position in shares of Alvotech during the second quarter valued at $6,376,000. Royce & Associates LP acquired a new stake in shares of Alvotech in the third quarter valued at $3,817,000. Marshall Wace LLP bought a new position in shares of Alvotech in the third quarter valued at about $2,326,000. BROOKFIELD Corp ON bought a new position in shares of Alvotech in the third quarter valued at about $2,244,000. Finally, Goldman Sachs Group Inc. acquired a new position in Alvotech during the 3rd quarter worth about $866,000.

About Alvotech

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

See Also

Analyst Recommendations for Alvotech (NASDAQ:ALVO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alvotech Right Now?

Before you consider Alvotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alvotech wasn't on the list.

While Alvotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines